Yes all great stuff @stockrock .... looking forward to NIH / LVAD readout
Not sure if I am having a blonde moment (I could have missed it), but has there been an update on this:
FDA CLEARS HEART DISEASE TRIAL AT HARVARD'S BOSTON CHILDREN’S HOSPITAL USING MESOBLAST'S CELL THERAPY IN CHILDREN WITH CONGENITAL HEART DISEASE
New York, USA, April 3; and Melbourne, Australia; April 4, 2017: Boston Children’s Hospital, the pediatric teaching hospital of Harvard University, and Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that the United States Food and Drug Administration (FDA ) has cleared the commencement of a 24-patient trial combining Mesoblast's proprietary allogeneic mesenchymal precursor cells (MPCs) with corrective heart surgery in children under the age of 5 with hypoplastic left heart syndrome (HLHS). The trial is sponsored and funded by the Boston Children’s Hospital with support from Bulens and Capozzi Foundation and the Ethan Lindberg Foundation.
Or this:
MD ANDERSON CANCER CENTER AND NATIONAL INSTITUTES OF HEALTH TO FUND CLINICAL TRIAL COMBINING TWO PROPRIETARY MESOBLAST TECHNOLOGIES FOR RAPID ENGRAFTMENT OF STEM CELL TRANSPLANTS IN CANCER PATIENTS
New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast's two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.
One of you medically inclined people on here might be able to put me out of my misery and furnish me with an answer ?
- Forums
- ASX - By Stock
- MSB
- Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial
Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial, page-16
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.370B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.16 | $3.120M | 2.623M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 21562 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 12729 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 44471 | 1.165 |
16 | 125573 | 1.160 |
9 | 146106 | 1.155 |
13 | 440061 | 1.150 |
3 | 16785 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 14865 | 6 |
1.175 | 27727 | 9 |
1.180 | 62713 | 10 |
1.185 | 58570 | 8 |
1.190 | 18205 | 5 |
Last trade - 12.18pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |